MedicalResearch.com Interview with:
Dr. Morton Scheinberg, MD, PhD
From Hospital Israelita Albert Einstein and Hospital AACD,
São Paulo, and
Clinica Dermatosineida, Maringa, Parana, Brazil.
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: That universal hair loss associated with a localized autoimmune reaction on the cells involved with the hair follicles can be halted with tofacitinib.
MedicalResearch.com: What should readers take away from your report?
Response: This is an opportunity for innovative oral therapy for alopecia universalis.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: Additional real life experience and clinical trial to be done.
MedicalResearch.com: Is there anything else you would like to add?
Response: This new therapy does not apply to baldness of endocrine origen which is more common
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Annals of Internal Medicine November 14 2016
Reversal of Alopecia Universalis by Tofacitinib: A Case Report
Morton Scheinberg, MD, PhD; Sineida Berbert Ferreira, MD
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
More Medical Research Interviews on MedicalResearch.com